Rheumatoid arthritis is a chronic autoimmune disorder causing inflammation of synovial joints, leading to pain, stiffness, ...

Tocilizumab, a biologic disease-modifying antirheumatic drug targeting interleukin 6, reduces disease activity more ...

Weaker immune response against COVID-19 may be attributed to the more targeted immunosuppressive mechanism of biologic DMARDs. Rheumatoid arthritis (RA) patients receiving biologic disease-modifying ...

Following the FDA approval of a vagus nerve stimulator for rheumatoid arthritis, supporters of the device’s use have lauded ...

A recent study unveiled at the ACR Convergence 2025 suggests that certain medications originally developed for diabetes and weight-loss treatment may also help reduce flare-ups in Rheumatoid Arthritis ...

A significant number of people with rheumatoid arthritis (RA) experience financial distress, particularly if they also suffer ...

The current obsession with inflammation may seem new, but at the University of Arizona’s Andrew Weil Medical Center for ...

Artiva remains on track to share initial clinical response data and conduct U.S. Food and Drug Administration (FDA) ...

DelveInsight's Rheumatoid Arthritis Market Insights report includes a comprehensive understanding of current treatment practices, rheumatoid arthritis emerging drugs, market share of individual ...

The management of rheumatoid arthritis (RA) has significantly improved, but a substantial number of patients still experience ...

CHICAGO -- Hitting rheumatoid arthritis (RA) early and hard, with targeted therapies as first-line treatment, appears to reduce the likelihood that it will reach the dreaded "difficult-to-treat" stage ...